GSK’s Jemperli In Search Of Lung Cancer Foothold And TIM-3 Combo Could Be Best Chance

Keytruda Head-To-Head Is Ambitious

Oct 05 2022

GSK is rebuilding its presence in oncology, and hopes Jemperli can be the backbone of its immunotherapy franchise. • Source: GSK